While Keros Therapeutics Inc has overperformed by 0.64%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KROS fell by -1.14%, with highs and lows ranging from $72.37 to $9.12, whereas the simple moving average jumped by 15.30% in the last 200 days.
On October 20, 2025, Wells Fargo started tracking Keros Therapeutics Inc (NASDAQ: KROS) recommending Overweight. A report published by BofA Securities on June 10, 2025, Downgraded its rating to ‘Neutral’ for KROS. Oppenheimer resumed its ‘Outperform’ rating for KROS, as published in its report on December 16, 2024. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Keros Therapeutics Inc (KROS)
Further, the quarter-over-quarter increase in sales is 49002.70%, showing a positive trend in the upcoming months.
Keros Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 3.33% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 21.11, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and KROS has an average volume of 663.07K. On a monthly basis, the volatility of the stock is set at 4.43%, whereas on a weekly basis, it is put at 3.01%, with a gain of 4.06% over the past seven days. Furthermore, long-term investors anticipate a median target price of $23.00, showing growth from the present price of $15.65, which can serve as yet another indication of whether KROS is worth investing in or should be passed over.
How Do You Analyze Keros Therapeutics Inc Shares?
Biotechnology giant Keros Therapeutics Inc (KROS) is based in the USA and is one of the largest companies in the market. When comparing Keros Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 49.95, there is a growth in quarterly earnings of 39.71%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 6.77%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 102.62% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
